MK-212 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H11ClN4.ClH
Molecular Weight	235.114
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.ClC1=CN=CC(=N1)N2CCNCC2

InChI

InChIKey=PFIZGLUIYAZQFU-UHFFFAOYSA-N

InChI=1S/C8H11ClN4.ClH/c9-7-5-11-6-8(12-7)13-3-1-10-2-4-13;/h5-6,10H,1-4H2;1H

HIDE SMILES / InChI

Molecular Formula	C8H11ClN4
Molecular Weight	198.653
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17415471 | https://www.ncbi.nlm.nih.gov/pubmed/23301527

MK-212 is a 5HT2C-receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A (IC50 values are 0.028 and 0.42 uM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively). A dose-dependent the effect of 5HT2C-receptor agonist MK-212 on mouse behavior was demonstrated. Intraperitoneal injection of MK-212 in high doses (0.5 and 1.0 mg/kg) increased blood level of corticosterone in mice and reduced their motor activity. In low doses of 0.1 and 0.2 mg/kg, the agonist reduced anxiety, but had no effect on motor activity. It is hypothesized that low doses of MK-212 exhibited anxiolytic activity in mice.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2c (5-HT2c) receptor 124 Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12055129 \| https://www.ncbi.nlm.nih.gov/pubmed/12970106 \| https://www.ncbi.nlm.nih.gov/pubmed/23301527	Agonist 2678		28.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cocaine addiction 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20520599 https://www.ncbi.nlm.nih.gov/pubmed/22886755	Primary		Preclinical	Unknown Approved Use Unknown
Anxiety 267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17415471 https://www.ncbi.nlm.nih.gov/pubmed/15075625	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.	1993 Mar	8450835
Serotonin(2C) receptors appear to mediate genetic sensitivity to cocaine-induced convulsions.	1999 Oct	10541732
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.	2000 Feb	10611640
Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.	2001 Jul-Aug	11509227
Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus.	2002 Sep 1	12196574
Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex.	2003 Aug	12721337
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.	2003 Sep	12970106
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.	2004 Aug	15322733
Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus.	2004 Feb	15075625
Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze.	2005 Nov	16133141
Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder.	2005 Sep	18568072
Inhibition of serotonin transporters by cocaine and meprylcaine through 5-TH2C receptor stimulation facilitates their seizure activities.	2005 Sep 28	16125150
5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats.	2006 Apr	16521035

Patents

Sample Use Guides

In Vivo Use Guide

The effects of MK-212 (10, 20, and 40 mg, orally), a centrally acting serotonin (5-HT) receptor agonist and placebo, on serum cortisol, prolactin, and growth hormone levels were studied in eight healthy men over 3-hr. MK-212 produced a dose-related increase in serum cortisol levels, with the 20- and 40-mg doses producing significant elevations. Serum prolactin levels were significantly elevated only by the 40-mg dose.

Route of Administration: Oral

In Vitro Use Guide

MK-212 (1 x 10(-7)M -- 1 x 10(-5)M) produced dose-dependent contractions of guinea pig ileum, taenia coil and rat fundus strip.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:01:59 GMT 2023` Edited by `admin` on `Fri Dec 15 15:01:59 GMT 2023`
Record UNII	8722D514RX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MK-212 HYDROCHLORIDE

Common Name

English

PYRAZINE, 2-CHLORO-6-(1-PIPERAZINYL)-, HYDROCHLORIDE

Systematic Name

English

PYRAZINE, 2-CHLORO-6-(1-PIPERAZINYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

MK-212 HCL

Code

English

MK-212-HCL

Code

English

PYRAZINE, 2-CHLORO-6-(1-PIPERAZINYL)-, MONOHYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

DRUG BANK

DBSALT002137